News

Eureka Therapeutics and City of Hope will jointly conduct a Phase 1 clinical trial of assessing Eureka’s investigational CAR T-cell therapy ET1402 for hepatocellular carcinoma (HCC), the most…

ProSciento and OWL Metabolomics are partnering to find eligible participants for clinical trials for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Results from a mouse study of nonalcoholic steatohepatitis were promising for Viking Therapeutics' oral therapy VK2809, now also in a Phase 2 trial.

SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than Nexavar in a Phase 3 trial.

Ocera Therapeutics has started the second part of a Phase 1/2a clinical trial of OCR-002 (ornithine phenylacetate) tablets as a treatment for a liver…

A study by Australia’s Westmead Institute has revealed an unexpected role for zinc in liver disease. Researchers at the institute’s Storr Liver Center showed that…

A new digital support platform, IO Loop, is helping patients stay connected online with doctors before, during, and after treatment. This helps patients track symptoms,…

Coffee consumption can dramatically cut one’s risk of developing hepatocellular carcinoma (HCC), a type of liver cancer, say researchers from Scotland’s University of Edinburgh who…

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb seeking approval for Opdivo…

Canadian patients with the autoimmune liver disease primary biliary cholangitis (PBC) saw the first approval of a new drug for their condition in more than…